Latest Data with ONO-4059 And Ibrutinib

Prof Simon Rule, Plymouth Hospital, Plymouth, UK, discusses data presented at EHA 2014 on the second-generation oral BTK inhibitor, ONO-4059.  One study presented relates to CLL, the other to non-Hodgkin’s lymphoma (NHL). In both studies, ONO-4059 shows promising results which might allow it to compete with ibrutinib. Prof Rule also outlines the benefits seen with ibrutinib in several haematological cancers, and a presents a poster showing 2-year ibrutinib toxicity data.

Year of Production:
Running Time:



Comments are closed.